Leavell Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Leavell Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.57M	Sell	5,175 -1,485	-22%	-$658K	0.09%	200
2026 Q1	$2.97M	Buy	6,660 +15	+0.2%	+$6.99K	0.12%	173
2025 Q4	$3.01M	Sell	6,645 -340	-5%	-$147K	0.13%	173
2025 Q3	$2.74M	Sell	6,985 -1,104	-14%	-$461K	0.12%	182
2025 Q2	$3.6M	Buy	8,089 +355	+5%	+$164K	0.16%	145
2025 Q1	$3.75M	Buy	7,734 +1,423	+23%	+$663K	0.19%	128
2024 Q4	$2.54M	Buy	6,311 +802	+15%	+$372K	0.12%	164
2024 Q3	$2.56M	Buy	5,509 +790	+17%	+$379K	0.13%	163
2024 Q2	$2.21M	Buy	4,719 +57	+1%	+$24.7K	0.12%	167
2024 Q1	$1.95M	Buy	+4,662	New	+$1.97M	0.11%	174

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Leavell Investment Management's VRTX Position: Q2 2026 in Review

Leavell Investment Management reduced its Vertex Pharmaceuticals (VRTX) stake by 22% in Q2 2026, selling an estimated $658K and leaving 5,175 shares worth $2.57M. The position accounts for 0.09% of the portfolio, ranked #200.

Leavell Investment Management first reported a position in VRTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $3.75M in Q1 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Leavell Investment Management held 5,175 shares of Vertex Pharmaceuticals worth $2.57M as of Q2 2026.
Leavell Investment Management sold 1,485 Vertex Pharmaceuticals shares in Q2 2026, an estimated $658K.
Vertex Pharmaceuticals made up 0.09% of Leavell Investment Management's portfolio in Q2 2026, its #200 holding.
Leavell Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Leavell Investment Management's Vertex Pharmaceuticals position peaked at $3.75M in Q1 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Leavell Investment Management's 13F filing for Q2 2026, filed 21 Jul 2026.